FDA Wrangles With Generic Exclusivity, Looks To Courts For Direction
Executive Summary
For FDA, resolving 180-day exclusivity issues may be as difficult as Lisbeth Salander’s quest to figure out Fermat’s Last Theorem.
You may also be interested in...
Former FDA Chief Counsel Elizabeth Dickinson Hailed For Her Expertise, Warmth And Mentorship
Dickinson, who joined the Office of Chief Counsel in 1994, retired on 24 September. Former colleagues note the impact she had within and outside the agency, particularly as the ‘legendary leader’ of the legal approach to generic drugs.
US FDA Gives Directions On Navigating Generic 180-Day Exclusivity Maze
Draft guidance sums up agency’s policies for determining exclusivity, clarifies when the clock starts for failure to market.
US FDA Gives Directions On Navigating Generic 180-Day Exclusivity Maze
Draft guidance sums up agency’s policies for determining exclusivity, clarifies when the clock starts for failure to market.